Back To TOP

We Focus on Access so
You Can Focus on Health

Connecting your patients to Tarceva® (erlotinib) tablets.
Welcome to Tarceva Access Solutions.

I am a
Learn More About
  • LEARN about treatment with Tarceva
  • NOW APPROVED as first-line therapy for metastatic non–small cell lung cancer (NSCLC) patients with exon 19 and 21 epidermal growth factor receptor (EGFR) mutations.
  • LEARN HOW the Genentech BioOncology Co-pay Card can help with the out-of-pocket costs for Tarceva
  • Download: new forms for enrollment in GATCF
  • Form Statement of Medical Necessity
  • Form Patient Authorization and Notice of Release of Information

Tarceva Indications and Important Safety Information


Advanced Non-Small Cell Lung Cancer (NSCLC)
Tarceva is indicated for:

  • The first-line treatment of patients with metastatic NSCLC whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
  • The maintenance treatment of patients with locally advanced or metastatic NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.
  • The treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen.

Limitations of use:

  • Tarceva is not recommended for use in combination with platinum-based chemotherapy.
  • Safety and efficacy of Tarceva have not been evaluated as first-line treatment in patients with metastatic NSCLC whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution.

Advanced Pancreatic Cancer

  • Tarceva in combination with gemcitabine is indicated for the first-line treatment of patients with locally advanced, unresectable, or metastatic pancreatic cancer

Important safety information


- Cases of serious interstitial lung disease (ILD), including fatal cases, have been reported.

- Hepatic failure, hepatorenal syndrome, and severe acute renal failure (all including fatal cases) and renal insufficiency have been reported.

- Gastrointestinal perforation (including fatal cases) has been reported.

- Bullous, blistering and exfoliative skin conditions, including cases suggestive of Stevens-Johnson syndrome/toxic epidermal necrolysis, which in some cases were fatal, have been reported.

- In the pooled incidences in the 3 monotherapy lung studies and the pancreatic carcinoma trial, serious adverse reactions, including fatal cases, such as myocardial infarction/ischemia, cerebrovascular accident, and microangiopathic hemolytic anemia with thrombocytopenia were reported.

- Corneal perforation or ulceration have been reported.

- Severe and fatal hemorrhage associated with INR elevations can occur when Tarceva and warfarin are used concurrently.

- Embryo-fetal toxicity. Tarceva is pregnancy category D. Women should be advised to avoid pregnancy or breastfeeding.


- Metastatic NSCLC – First-Line Treatment of Patients With EGFR Mutations:

- Diarrhea, asthenia, rash, cough, dyspnea, and decreased appetite.

- Advanced NSCLC – Maintenance and Second/Third-Line Treatment:

- Rash and diarrhea.

- Advanced Pancreatic Cancer – Tarceva Administered Concurrently with Gemcitabine:

- Fatigue, rash, nausea, anorexia, and diarrhea.

You may report side effects to the FDA at (800) FDA-1088 or You may also report side effects to Genentech at (888) 835-2555.

For additional Important Safety Information, please see accompanying full prescribing information.

Tarceva® and its logo are trademarks of OSI Pharmaceuticals, LLC, an affiliate of Astellas Pharma US, Inc.

The Access Solutions logo is a registered trademark of Genentech, Inc.